Stroke trial aims to prevent second attacks with tailored blood thinners
NCT ID NCT06853535
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether using a blood test to guide antiplatelet therapy can better prevent recurrent strokes in people who have had a mild stroke or transient ischemic attack (TIA). About 5,100 participants will be assigned to either standard clopidogrel or ticagrelor based on their platelet function. The goal is to see if ticagrelor reduces the risk of another stroke within 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ticagrelor and clopidogrel (antiplatelet drugs)
What this could lead to
If successful, this could provide a more effective antiplatelet strategy for stroke patients who don't respond well to clopidogrel, reducing their risk of another stroke.
What could go wrong
This is a large Phase 3 trial, but it only includes patients with mild strokes or TIAs, so results may not apply to all stroke patients. There is also a risk of bleeding with antiplatelet therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••